

GLPG2938

## Chemical Properties


CAS No. : 2130996-00-6

Formula: C<sub>20</sub>H<sub>19</sub>F<sub>6</sub>N<sub>7</sub>O<sub>2</sub>

Molecular Weight: 503.4

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	GLPG2938 (1-(2-Ethoxy-6-(trifluoromethyl)pyridin-4-yl)-3-((5-methyl-6-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)pyridazin-3-yl)methyl)urea) is a potent and selective antagonist of S1P2.
Targets(IC50)	LPL Receptor,S1P Receptor
In vitro	GLPG2938 significantly prevents the S1P-mediated contraction at all tested concentrations[1].
In vivo	In all species ,GLPG2938 shows good pharmacokinetics, with long half-life,low clearance,and good bioavailability.

## Solubility Information

Solubility	DMSO: 60 mg/mL (119.19 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.97 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9865 mL	9.9325 mL	19.8649 mL
5 mM	0.3973 mL	1.9865 mL	3.973 mL
10 mM	0.1986 mL	0.9932 mL	1.9865 mL
50 mM	0.0397 mL	0.1986 mL	0.3973 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis[J]. Journal of Medicinal Chemistry, 2021, 64(9):6037-6058.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481